Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Squibb/Novo-Nordisk

Executive Summary

CNS drug development and co-marketing agreement, announced by Squibb May 2, expands relationship between the firms beyond insulin to central nervous system disease therapies for depression, anxiety and psychosis. The deal was signed in first quarter and announced by Squibb at its annual meeting. In depression area, Novo-Nordisk has been working on dopamine reuptake inhibitors. GBR-12909 is currently in Phase II clinicals in Europe. Other CNS compounds are: FD- 10571, a non-benzodiazapine anxiolytic; FG-8119, a partial benzodiazapine receptor agonist; and fexometine,a 5-HT reuptake inhibitor with antidepressant properties.

You may also be interested in...



Execs On The Move: New CFOs At Pacific Biosciences, Aziyo Biologics; Illumina Gets Marketing Boss

Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.

FDA Grant Establishes Complex Generics Center To Increase Access

Complex active ingredients, formulations, routes of delivery, and drug-device combination products are to receive greater attention as part of attempts to facilitate competition after the US FDA awarded a $5m grant to establish a dedicated research center.

What’s Next? Five Things To Look Out For In October

In October, the period during which Mylan may complete its merger with Upjohn will begin, while the FDA will begin holding monthly stakeholder meetings ahead of the third iteration of the Generic Drug User Fee Amendments program, also known as GDUFA III.

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel